JP2020510433A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510433A5
JP2020510433A5 JP2019547457A JP2019547457A JP2020510433A5 JP 2020510433 A5 JP2020510433 A5 JP 2020510433A5 JP 2019547457 A JP2019547457 A JP 2019547457A JP 2019547457 A JP2019547457 A JP 2019547457A JP 2020510433 A5 JP2020510433 A5 JP 2020510433A5
Authority
JP
Japan
Prior art keywords
raav
capsid
variant
sequence
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510433A (ja
JP7211960B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020470 external-priority patent/WO2018160849A1/en
Publication of JP2020510433A publication Critical patent/JP2020510433A/ja
Publication of JP2020510433A5 publication Critical patent/JP2020510433A5/ja
Priority to JP2023002799A priority Critical patent/JP7671790B2/ja
Application granted granted Critical
Publication of JP7211960B2 publication Critical patent/JP7211960B2/ja
Priority to JP2025068834A priority patent/JP2025114604A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547457A 2017-03-01 2018-03-01 眼疾患の遺伝子治療 Active JP7211960B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023002799A JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療
JP2025068834A JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465649P 2017-03-01 2017-03-01
US62/465,649 2017-03-01
US201762469642P 2017-03-10 2017-03-10
US62/469,642 2017-03-10
PCT/US2018/020470 WO2018160849A1 (en) 2017-03-01 2018-03-01 Gene therapy for ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023002799A Division JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療

Publications (3)

Publication Number Publication Date
JP2020510433A JP2020510433A (ja) 2020-04-09
JP2020510433A5 true JP2020510433A5 (OSRAM) 2021-03-18
JP7211960B2 JP7211960B2 (ja) 2023-01-24

Family

ID=63370488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547457A Active JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療
JP2023002799A Active JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023002799A Active JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Country Status (11)

Country Link
US (2) US11564996B2 (OSRAM)
EP (2) EP4656244A2 (OSRAM)
JP (3) JP7211960B2 (OSRAM)
KR (3) KR102545070B1 (OSRAM)
CN (2) CN110582572A (OSRAM)
AU (2) AU2018228881B2 (OSRAM)
BR (1) BR112019017327A2 (OSRAM)
CA (1) CA3054136A1 (OSRAM)
IL (2) IL314284A (OSRAM)
RU (1) RU2019130004A (OSRAM)
WO (1) WO2018160849A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103740A1 (en) * 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
JP7640549B2 (ja) * 2019-12-12 2025-03-05 ノバルティス アーゲー 注射デバイス及び注射溶液移し替えシステム
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20220387627A1 (en) * 2021-06-03 2022-12-08 Hope for Hasti Vectors and gene therapy for treating cornelia de lange syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
EP1286703B1 (en) 2000-06-01 2009-08-05 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
WO2002082904A2 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US20080050357A1 (en) 2003-08-01 2008-02-28 Claes Gustafsson Systems and Methods for Antibody Engineering
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2008065430A2 (en) * 2006-12-01 2008-06-05 Oxford Biomedica (Uk) Limited Promoter construct
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
CA2864879C (en) * 2012-02-17 2021-07-20 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
BR112014029807A2 (pt) 2012-06-08 2017-06-27 Ethris Gmbh administração pulmonar de rna mensageiro
NZ704275A (en) 2012-07-11 2016-09-30 Univ Florida Aav-mediated gene therapy for rpgr x-linked retinal degeneration
CA2881081C (en) 2012-08-08 2017-04-18 Nihon Parkerizing Co., Ltd. Metal surface treatment liquid, surface treatment method for metal base, and metal base obtained thereby
EP2954051B1 (en) 2013-02-08 2019-03-27 The Trustees Of The University Of Pennsylvania Modified aav8 capsid for gene transfer for retinal therapies
CN105209619B (zh) * 2013-03-11 2018-10-12 泰莱托恩基金会 miR-204和miR-211及其用途
BR112015021884A8 (pt) * 2013-03-15 2019-11-26 Childrens Hospital Philadelphia vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica
US9158889B2 (en) * 2013-04-26 2015-10-13 Oral4D Systems Ltd. Electronic dental charting
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US10155794B2 (en) * 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
US10392622B2 (en) * 2014-08-01 2019-08-27 The Trustees Of The University Of Pennsylvania Compositions and methods for self-regulated inducible gene expression

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
JP7162021B2 (ja) 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
JP2021106619A5 (OSRAM)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2021087431A5 (OSRAM)
JP2020528734A5 (OSRAM)
JP2020514286A5 (OSRAM)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2020510428A5 (OSRAM)
JP2019503649A5 (OSRAM)
JP2018148927A5 (OSRAM)
JP2020522269A5 (OSRAM)
JP2020513811A5 (OSRAM)
JP2018537984A5 (OSRAM)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2018506261A5 (OSRAM)
JP2020510433A5 (OSRAM)
AU2022407655A1 (en) Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
AU2023234604A1 (en) Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector
JP2018526994A5 (OSRAM)
RU2019130004A (ru) Генная терапия при глазных заболеваниях
JPWO2022015715A5 (OSRAM)
JPWO2021108809A5 (OSRAM)
WO2023111106A1 (en) Fukutin related protein gene transfer increase using modified itr sequences
AU2022407548A1 (en) Compositions comprising kozak sequences selected for enhanced expression